News and press
Introducing Preologi – the UK’s first provider of the Galleri® test
Bringing next-generation screening for cancer and heart disease to UK patients — starting with a landmark cancer detection program.
Working with GRAIL – A UK First
Preologi is proud to be the first UK company to work with GRAIL, Inc., the manufacturer of the Galleri® multi-cancer early detection (MCED) test — widely regarded as one of the most significant advances in cancer screening in a generation.
The Galleri® test uses a single blood sample to screen for a cancer signal shared across more than 50 types of cancer, most of which have no current standard screening pathway. The Galleri® test can then predict the cancer signal origin.
Preologi is the UK’s first provider of the Galleri® test – and screening is now available.
Preologi’s founding mission is to deliver early clinical access to the latest evidence-based technologies that protect against premature death. The company, founded by Dr Michael Hickman, is exclusively science-led, adopting only rigorously validated innovations and making them available directly to patients and the wider UK healthcare sector.
Dr Michael Hickman is a highly respected cardiologist whose career has been defined by a commitment to advancing patient outcomes by combining clinical excellence and a technology focus. The founding of Preologi represents the next chapter in that commitment — harnessing the most exciting diagnostic technologies available and making them accessible to patients across the UK.
“The science of early detection is advancing rapidly. Now the opportunity to intervene earlier — and more effectively — than ever before is genuinely ground-breaking. At Preologi, we are focussed on reducing the blight of unnecessary premature deaths witnessed daily by clinicians across the UK. We have brought together an exceptional clinical team and partnered with world-leading innovators to give our clients access to that science today.”
Dr Michael Hickman, Founder, Preologi
Book a Galleri® cancer testWondering whether the Galleri® test is right for you?
Who should consider taking the Galleri® test?
The Galleri® test is recommended for use in adults with an elevated risk of cancer, such as those with a family history of cancer or those over 50 years old. This may also include individuals with a personal history of cancer, smokers or former smokers, and anyone wishing to take a proactive approach to their health. Your Preologi clinician will help assess whether the test is appropriate for you.
Am I eligible for the Galleri® test if I have previously had cancer?
Yes. The Galleri® test can be an extremely helpful adjunct in managing your long-term health when you are a cancer survivor. Patients must undergo all recommended post-cancer surveillance tests and follow-ups as recommended by their oncologists. The Galleri® test adds additional beneficial screening for such individuals who, unfortunately, are at increased risk of further cancer diagnosis when compared to the normal population.
Is this the same as existing cancer screening programmes?
No. The Galleri® test is a complementary tool and not a replacement for NHS screening programmes such as bowel, breast, or cervical detection. It covers many cancers for which no routine detection currently exists, providing an additional layer of screening. We recommend continuing with all age-appropriate NHS screening alongside the Galleri® test.
Is the Galleri® test available in the UK?
Yes. Preologi is the first UK provider of the Galleri® test and is available to book now at Preologi.com.
Find out more“Outstanding. 10/10 for professionalism, care, knowledge and efficiency.”
Verified patient, TOPDOCTOR UK
Reviews